325 related articles for article (PubMed ID: 21558430)
21. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
22. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.
van den Brand JA; van Dijk PR; Hofstra JM; Wetzels JF
J Am Soc Nephrol; 2014 Jan; 25(1):150-8. PubMed ID: 24029426
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of membranous glomerulonephritis: analysis of data from the Italian Renal Biopsy Registry].
Garozzo M; Puliatti D; Battaglia GG
G Ital Nefrol; 2011; 28(4):425-30. PubMed ID: 21809312
[TBL] [Abstract][Full Text] [Related]
25. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy.
Kosmadakis G; Filiopoulos V; Smirloglou D; Skarlas P; Georgoulias C; Michail S
Ren Fail; 2010 Jun; 32(5):566-71. PubMed ID: 20486839
[TBL] [Abstract][Full Text] [Related]
26. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.
Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC;
J Am Soc Nephrol; 2005 Apr; 16(4):1061-8. PubMed ID: 15716334
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
Choudhry S; Bagga A; Hari P; Sharma S; Kalaivani M; Dinda A
Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy.
Idasiak-Piechocka I; Oko A; Łochyńska-Bielecka K; Skrobańska B
Kidney Blood Press Res; 2009; 32(4):263-7. PubMed ID: 19776643
[TBL] [Abstract][Full Text] [Related]
29. Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment.
de Goeij MC; Liem M; de Jager DJ; Voormolen N; Sijpkens YW; Rotmans JI; Boeschoten EW; Dekker FW; Grootendorst DC; Halbesma N;
Nephron Clin Pract; 2012; 121(1-2):c73-82. PubMed ID: 23128440
[TBL] [Abstract][Full Text] [Related]
30. [The late results of treating membranous glomerulonephritis].
Belovezhdov N; Robeva R; Dimitrova V
Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
32. Idiopathic membranous nephropathy: diagnosis and treatment.
Fervenza FC; Sethi S; Specks U
Clin J Am Soc Nephrol; 2008 May; 3(3):905-19. PubMed ID: 18235148
[TBL] [Abstract][Full Text] [Related]
33. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
34. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study.
Banfi G; Moriggi M; Sabadini E; Fellin G; D'Amico G; Ponticelli C
Clin Nephrol; 1991 Aug; 36(2):53-9. PubMed ID: 1934660
[TBL] [Abstract][Full Text] [Related]
35. [Quadritherapy with cyclosporine for membranous lupus nephropathy].
Matsumoto H; Okada T; Nagaoka Y; Tomaru R; Iwasawa H; Wada T; Nakao T
Nihon Jinzo Gakkai Shi; 2003 Oct; 45(7):689-94. PubMed ID: 14631764
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions.
Faedda R; Pirisi M; Satta A; Tanda F; Bartoli E
Clin Nephrol; 1996 Oct; 46(4):237-44. PubMed ID: 8905208
[TBL] [Abstract][Full Text] [Related]
37. New aspects of posttransplant nephrotic syndrome: clinicopathologic correlations with outcomes.
Yakupoğlu U; Baranowska-Daca E; Suki WN; Truong LD
Transplant Proc; 2004; 36(1):139-43. PubMed ID: 15013326
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of untreated patients with idiopathic membranous nephropathy.
Schieppati A; Mosconi L; Perna A; Mecca G; Bertani T; Garattini S; Remuzzi G
N Engl J Med; 1993 Jul; 329(2):85-9. PubMed ID: 8510707
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome.
Zucchelli P; Ponticelli C; Cagnoli L; Passerini P
Nephrol Dial Transplant; 1987; 2(2):73-8. PubMed ID: 3112653
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcome of patients with idiopathic membranous nephropathy.
Ríhová Z; Merta M; Maixnerová D; Honsová E; Reiterová J; Rysavá R; Zabka J; Tesar V
Prague Med Rep; 2006; 107(2):189-98. PubMed ID: 17066739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
